Skip to main content
Premium Trial:

Request an Annual Quote

BD Diagnostics, Diagenode Launch BD Max Flu A/B Test in Europe

Premium

BD Diagnostics, a division of Becton Dickinson, and Belgium's Diagenode this week announced the European launch of Diagenode's influenza A and B assay for use on the BD Max molecular testing system.

The assay is the first to be commercialized through BD's partner program, under which BD has tapped a number of third-party assay developers to create a menu of in vitro diagnostic tests for the BD Max.

The new Flu A/B primers and probes recently received a CE Mark and are validated to run on the BD Max using the BD Max RNA extraction kit RNA-3 open system reagent, which "standardizes the extraction process and offers ease of use and improved laboratory workflow," BD said in a statement.

BD unveiled the new BD Max "open" system in Europe and introduced Diagenode as the first development partner in May 2011 (PCR Insider, 5/12/2011). The platform is a six-color version of the company's real-time PCR-based BD Max system that is intended to enable labs to perform both IVD and laboratory-developed tests.

BD's partnership with Diagenode also covers assays for enteric and central nervous system diseases.

Other participants in BD's partnership program include Lab21, which is developing an assay for Aspergillus fungal infections (PCR Insider, 8/4/2011), and Italy's Biodiversity, which is working on a menu of tests for infectious agents in immunocompromised patients (PCR Insider, 8/18/2011).

BD Diagnostics has not yet named any US-based assay-development partners.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.